Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company pioneering viral immunotherapies for solid tumor treatment. This page serves as the definitive source for official updates on the company's innovative adenovirus and herpes simplex virus (HSV) platform developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing therapy advancements, peer-reviewed research collaborations, and manufacturing updates relevant to CADL's immuno-oncology pipeline.
Key content categories include phase trial results, FDA communications, intellectual property developments, and executive leadership announcements. All materials are sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page for streamlined access to Candel Therapeutics' latest developments in cancer immunotherapy. Check regularly for updates on their gmci™ and rqnestin34.5 platforms as they progress through clinical evaluation.
Candel Therapeutics announced on April 17, 2023, that the FDA has granted fast track designation for its investigational viral immunotherapy CAN-2409 combined with valacyclovir and pembrolizumab. This designation aims to expedite the drug's development for patients with late-stage non-small cell lung cancer (NSCLC) resistant to first-line therapies. CAN-2409 targets patients without molecular driver mutations and aims to enhance survival rates and delay disease progression. Clinical trial data revealed a 77% disease control rate in a subset of patients with previous treatment failures. The company plans to present updated data from the ongoing Phase 2 trial in the third quarter of 2023, showcasing the potential of CAN-2409 in treating various solid tumors.
Candel Therapeutics, Inc. (Nasdaq: CADL) reported financial results for Q4 and FY 2022, showcasing promising advancements in its viral immunotherapy programs. The company extended its cash runway into Q2 2024 with cash and equivalents of $70.1 million, down from $82.6 million in 2021. Notably, CAN-2409 demonstrated a 77% disease control rate in non-small cell lung cancer patients. Candel anticipates multiple clinical data readouts in 2023, including topline results from its prostate cancer trial in Q4 2024. Despite a net loss of $5.1 million for Q4 2022, the company's strategic partnerships and ongoing trials bolster its potential to innovate cancer treatments.
Candel Therapeutics (Nasdaq: CADL) announced that CEO Paul Peter Tak will participate in a fireside chat at the Guggenheim 2023 Healthcare Talks Oncology Day on February 8, 2023, at 3:20 p.m. EST. This event will occur at the St. Regis Hotel in New York City. A live webcast can be accessed under the 'Events and Presentations' section on Candel's website, with a replay available for 30 days after the event.
Candel is focused on developing novel viral immunotherapies to treat cancer, utilizing genetically modified adenovirus and herpes simplex virus platforms. Their lead candidates are CAN-2409 and CAN-3110.
Candel Therapeutics, a clinical stage biopharmaceutical company focused on viral immunotherapies, announced that CEO Paul Peter Tak will participate in a virtual fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference. The event is scheduled for January 19, 2023, at 11:30 am EST. A live webcast will be available on the company’s website, with an archive accessible for 90 days post-event. Candel is known for its innovative approaches to cancer treatment, employing genetically modified viruses to enhance anti-tumor immune responses.
Candel Therapeutics (Nasdaq: CADL) presented promising data from its oncology pipeline, highlighting CAN-2409's 77% disease control rate in advanced non-small cell lung cancer patients and CAN-3110's median overall survival of 11.6 months in recurrent high-grade glioma. The company plans to prioritize CAN-3110 for further development and will not pursue phase 3 trials for CAN-2409 in glioma. Additionally, Candel announced a partnership with the University of Pennsylvania to enhance CAR-T cell therapies using its enLIGHTEN™ Discovery Platform. Cash reserves were reported at $77.2M, ensuring operations into Q1 2024.
Candel Therapeutics (Nasdaq: CADL) will host its first virtual R&D Day on December 6, 2022, presenting new clinical data from its phase 2 trial of CAN-2409 in late-stage non-small cell lung cancer (NSCLC) and CAN-3110 in high-grade glioma. The event will showcase insights from leading experts in immunology and oncology, discussing therapeutic combination opportunities and the scientific rationale behind Candel's collaboration with the University of Pennsylvania using the enLIGHTEN™ discovery platform. An interactive Q&A session will follow the presentations.
Candel Therapeutics presented updated results from its phase 1 trial of CAN-3110 for recurrent high-grade glioma (rHGG) at the SNO Annual Meeting. The trial involved 41 patients, with no dose-limiting toxicities observed. The median overall survival was reported at 11.6 months post-administration, with one patient achieving a complete response lasting over a year. The treatment showed positive effects on T cell activation and diversity, suggesting a shift in the tumor microenvironment. Future studies will explore the impact of multiple CAN-3110 injections on survival.
Candel Therapeutics, Inc. (Nasdaq: CADL) presented late-breaking data from a phase 1 trial of its lead viral immunotherapy, CAN-2409, combined with nivolumab for high-grade glioma patients. The combination showed promising results, being well tolerated with no significant added toxicity. It induced systemic immune activation and improved median overall survival (mOS) for patients with methylated MGMT promoter to 30.6 months after gross total resection. The trial supports the potential therapeutic synergy between CAN-2409 and immune checkpoint inhibitors.
